Spanish scientists have made a groundbreaking discovery in the fight against pancreatic cancer, a disease notoriously difficult to treat. In a recent study, a team led by Mariano Barbacid from the CNIO’s Experimental Oncology Group has developed a novel approach to targeting KRAS, a gene altered in about 90% of pancreatic cancers. This gene has been a major challenge due to the rapid development of resistance in tumors, even with the recently approved drugs targeting it.
Instead of focusing on KRAS at a single point, the researchers at CNIO managed to shut down the same cancer pathway at three key points simultaneously. In mouse models, this innovative strategy led to the complete and permanent disappearance of tumors, without causing significant side effects. The scientists achieved this by combining three agents: an experimental KRAS inhibitor called daraxonrasib, the lung cancer drug afatinib, and a protein-degrading compound known as SD36. When tested in three different mouse models of the most common form of pancreatic cancer, the treatment resulted in strong and lasting tumor regression, preventing resistance from emerging.
The authors express optimism, stating that these studies open a path to designing combined therapies that could improve patient survival. However, Barbacid emphasizes that the therapy is not yet ready for clinical trials, highlighting the need for further research before it can be tested in humans. Despite this, experts believe the study marks a significant shift after decades of limited progress, offering renewed hope that pancreatic cancer may one day become more treatable.
Interestingly, earlier reports from Qazinform (https://qazinform.com/) News Agency mentioned that MIT researchers had successfully synthesized a complex fungal compound known as verticillin A, discovered over 50 years ago and long considered a potential anti-cancer agent. This development further underscores the potential for innovative treatments in cancer research.
This study not only presents a promising new approach to treating pancreatic cancer but also invites further discussion and research in the field. As the scientific community continues to explore new avenues, the hope is that these advancements will lead to more effective treatments and, ultimately, better outcomes for patients.
